Abiopharma

🔍 Tameron David (Executive)

Company: BKV Corp (BKV)

Report Date: 2026-06-30

Detailed Transactions and Holdings:

• Acquired 920 shares of Common Stock at $23.0775 per share (Direct)
  Date: 2026-06-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 62,845.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-30 | Code: H | nature_of_ownership: By Son | shares_owned_after: 300.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-30 | Code: H | nature_of_ownership: By Son | shares_owned_after: 300.00

Footnotes:

• F1: The shares were acquired under the BKV Corporation Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
• F2: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the lesser of (i) closing price of the Issuer's common stock on the first trading day of the offering period, January 1, 2026, or (ii) closing price of the Issuer's common stock on the last trading day of the offering period, June 30, 2026.